Literature DB >> 20042619

Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.

Yanet Climent1, Daniel Yero, Isabel Martinez, Alejandro Martín, Keith A Jolley, Franklin Sotolongo, Martin C J Maiden, Rachel Urwin, Rolando Pajón.   

Abstract

In response to epidemic levels of serogroup B meningococcal disease in Cuba during the 1980s, the VA-MENGOC-BC vaccine was developed and introduced into the National Infant Immunization Program in 1991. Since then the incidence of meningococcal disease in Cuba has returned to the low levels recorded before the epidemic. A total of 420 Neisseria meningitidis strains collected between 1983 and 2005 in Cuba were analyzed by multilocus sequence typing (MLST). The set of strains comprised 167 isolated from disease cases and 253 obtained from healthy carriers. By MLST analysis, 63 sequence types (STs) were identified, and 32 of these were reported to be a new ST. The Cuban isolates were associated with 12 clonal complexes; and the most common were ST-32 (246 isolates), ST-53 (86 isolates), and ST-41/44 (36 isolates). This study also showed that the application of VA-MENGOC-BC, the Cuban serogroup B and C vaccine, reduced the frequency and diversity of hypervirulent clonal complexes ST-32 (vaccine serogroup B type-strain) and ST-41/44 and also affected other lineages. Lineages ST-8 and ST-11 were no longer found during the postvaccination period. The vaccine also affected the genetic composition of the carrier-associated meningococcal isolates. The number of carrier isolates belonging to hypervirulent lineages decreased significantly after vaccination, and ST-53, a sequence type common in carriers, became the predominant ST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042619      PMCID: PMC2832447          DOI: 10.1128/JCM.01653-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  53 in total

Review 1.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

2.  [Carriers of Neisseria meningitidis among children from a primary school].

Authors:  Isabel Martínez; Omar López; Franklin Sotolongo; Mayelin Mirabal; Antonio Bencomo
Journal:  Rev Cubana Med Trop       Date:  2003 Sep-Dec

3.  Genotypic characterization of Neisseria meningitidis serogroup B strains circulating in China.

Authors:  Li Yang; Zhujun Shao; Xiaobing Zhang; Li Xu; Junping Peng; Xingye Xu; Xiaofeng Liang; Yipeng Qi; Qi Jin
Journal:  J Infect       Date:  2008-01-22       Impact factor: 6.072

4.  Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine.

Authors:  L G Milagres; M C Gorla; C T Sacchi; M M Rodrigues
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

5.  Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application.

Authors:  Franklin Sotolongo; Concepción Campa; Victoria Casanueva; Esther María Fajardo; Iván Edelberto Cuevas; Noel González
Journal:  MEDICC Rev       Date:  2007-10       Impact factor: 0.583

6.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

Review 7.  Molecular typing of meningococci: recommendations for target choice and nomenclature.

Authors:  Keith A Jolley; Carina Brehony; Martin C J Maiden
Journal:  FEMS Microbiol Rev       Date:  2006-12-01       Impact factor: 16.408

8.  Stability of PorA during a meningococcal disease epidemic.

Authors:  A F Devoy; K H Dyet; D R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

9.  MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.

Authors:  Philipp Oster; Diana Lennon; Jane O'Hallahan; Kim Mulholland; Stewart Reid; Diana Martin
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

10.  Phenotypic and genotypic changes in a new clone complex of Neisseria meningitidis causing disease in The Netherlands, 1958-1990.

Authors:  R J Scholten; J T Poolman; H A Valkenburg; H A Bijlmer; J Dankert; D A Caugant
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

View more
  9 in total

1.  First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.

Authors:  Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark
Journal:  Pediatrics       Date:  2015-05       Impact factor: 7.124

2.  Meningococcal disease serogroup C.

Authors:  Félix O Dickinson; Antonio E Pérez; Iván E Cuevas
Journal:  Risk Manag Healthc Policy       Date:  2012-03-08

3.  Cross-protection induced by VA-MENGOC-BC® vaccine.

Authors:  Rolando Felipe Ochoa-Azze
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

4.  Survival of Neisseria meningitidis outside of the host: environmental effects and differences among strains.

Authors:  C L Swain; D R Martin; D Sim; T W Jordan; J K Mackichan
Journal:  Epidemiol Infect       Date:  2017-11-06       Impact factor: 4.434

5.  Characterization of Carriage Isolates of Neisseria meningitides in the Adolescents and Young Adults Population of Bogota (Colombia).

Authors:  Jaime Moreno; Melissa Hidalgo; Carolina Duarte; Olga Sanabria; Jean Marc Gabastou; Ana Belén Ibarz-Pavon
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

Review 6.  Carriage of Neisseria Meningitidis in Low and Middle Income Countries of the Americas and Asia: A Review of the Literature.

Authors:  Lidia Serra; Jessica Presa; Hannah Christensen; Caroline Trotter
Journal:  Infect Dis Ther       Date:  2020-04-02

7.  Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.

Authors:  Margherita Bodini; Alessandro Brozzi; Maria Giuliani; Hanna Nohynek; Anni Vainio; Markku Kuusi; Rosita De Paola; Mariagrazia Pizza; Duccio Medini; Maija Toropainen; Laura Serino; Alessandro Muzzi
Journal:  mSphere       Date:  2020-09-16       Impact factor: 4.389

Review 8.  Global practices of meningococcal vaccine use and impact on invasive disease.

Authors:  Asad Ali; Rabab Zehra Jafri; Nancy Messonnier; Carol Tevi-Benissan; David Durrheim; Juhani Eskola; Florence Fermon; Keith P Klugman; Mary Ramsay; Samba Sow; Shao Zhujun; Zulfiqar Bhutta; Jon Abramson
Journal:  Pathog Glob Health       Date:  2014-01       Impact factor: 2.894

Review 9.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Authors:  Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer
Journal:  Vaccine       Date:  2020-08-30       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.